Perfil
Yoshihiko Futamura is the founder of Hinge Therapeutics, Inc. He held the title of Director at the company, and was involved in both founding and business development job functions.
Cargos activos de Yoshihiko Futamura
| Empresas | Cargo | Inicio |
|---|---|---|
Hinge Therapeutics, Inc.
 Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura. | Fundador | - |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Hinge Therapeutics, Inc.
Hinge Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Hinge Therapeutics, Inc. is an early-stage biopharmaceutical company based in Torrance, CA. The private company focuses on developing small-molecule therapeutics against traditionally undruggable/challenging targets for unmet medical needs. The company's proprietary technology, the Hinge drug discovery platform, has generated several novel inactivators against targets which are traditionally targeted only by large molecules such as antibody and siRNA. The current areas of interest include bleeding disorders, solid tumors, cardiovascular diseases, CNS, rare disease, and anti-aging. Hinge Therapeutics is seeking investors/partners who can help them advance their programs while further establishing their "Hinge drug discovery platform" which can be applied to many other challenging targets. The company was founded by Yoshihiko Futamura, and the CEO is Akiko Futamura. | Health Technology |
- Bolsa de valores
- Insiders
- Yoshihiko Futamura
